Appili Therapeutics Inc.
APLI.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 66.70% | -60.38% | -88.23% | -88.23% | -89.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.70% | -60.38% | -88.23% | -88.23% | -89.47% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 66.70% | -60.38% | -88.23% | -88.23% | -89.47% |
| SG&A Expenses | -11.41% | -10.72% | -12.29% | -15.11% | -24.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.55% | -27.68% | -7.24% | 11.35% | 10.41% |
| Operating Income | 39.84% | 26.03% | -0.57% | -21.55% | -24.98% |
| Income Before Tax | 28.55% | 32.22% | 41.29% | 30.92% | 25.92% |
| Income Tax Expenses | 18,400.00% | 399.17% | -16.51% | -74.66% | -99.20% |
| Earnings from Continuing Operations | 26.00% | 30.26% | 40.93% | 31.74% | 26.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.00% | 30.26% | 40.93% | 31.74% | 26.85% |
| EBIT | 39.84% | 26.03% | -0.57% | -21.55% | -24.98% |
| EBITDA | 39.88% | 26.07% | -0.57% | -21.60% | -25.00% |
| EPS Basic | 27.62% | 30.41% | 40.95% | 31.17% | 26.69% |
| Normalized Basic EPS | 30.00% | 32.35% | 41.67% | 30.77% | 23.86% |
| EPS Diluted | 27.62% | 30.41% | 40.95% | 31.17% | 26.69% |
| Normalized Diluted EPS | 30.00% | 32.35% | 41.67% | 30.77% | 23.86% |
| Average Basic Shares Outstanding | 1.46% | 0.00% | 0.00% | 0.00% | 0.03% |
| Average Diluted Shares Outstanding | 1.46% | 0.00% | 0.00% | 0.00% | 0.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |